Loading stock…

TG Therapeutics, Inc. (TGTX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

TG Therapeutics, Inc.

TGTXMarket cap $7.51BPrice $53.0

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops and sells treatments for B-cell diseases and autoimmune disorders, anchored by Briumvi, its FDA-approved multiple sclerosis drug. TG Therapeutics went from a cash-burning clinical-stage biotech to profitable commercial player in record time, proving a small biotech can actually compete with pharma giants.

In Bastion Portfolios?

52W Return+53%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+505%10

Revenue Forecast

Rev CAGR (1y)+55%10

Rev CAGR (3y)+37%10

Rev CAGR (5y)+29%10

Earnings Forecast

EPS Growth Y+1-68%1

EPS Growth Y+2+174%10

EPS Growth Y+3+36%9

Quality

Margins

EBIT Margin17%7

Net Income Margin55%10

Free Cash Flow Margin2%3

Debt

Net Debt/EBITDA1.55

Efficiency

ROE100%10

ROA38%10

Earnings Stability66

GEAR+VERY STRONG91

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)272

P/E Ratio (Forward 3y)145

P/BV12.41

EV Multiples

EV/EBITDA Fwd331

EV/EBIT Fwd362

Yield

Free Cash Flow Yield0.2%3

Dividend Yieldna–

Momentum

Short term

1 month return-5%5

3 month return-7%4

YTD return+78%10

Mid term

Price vs 52wHigh89%8

1 year return+48%9

Long term

3 year return+581%10

5 year return+68%6

Risk Shield

Price Risk

Beta0.39

Volatility45%4

Free Cash Flow

Free Cash Flow Margin2%3

Free Cash Flow Yield0.2%3

Quality

ROCE14%7

Earnings Stability66

Net Debt/EBITDA1.55

02Growth

Is it actually growing, and how fast?

TGTXTG Therapeutics

Revenue FY25$616M

GROWTH RATING↗

VERY STRONG97 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+505%10

Revenue, next 1Y+55%10

Revenue, next 3Y, CAGR+37%10

Revenue, next 5Y, CAGR+29%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-68%1

EPS growth, FY27E+174%10

EPS growth, FY28E+36%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 97% of companies worldwide.

Revenue grew 505%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 37%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 29%/yr over five years.10/10

WATCH

Revenue grew 505%/yr over the last 3 years; forecasts see it cooling to 37%/yr.

Earnings are set to grow in step with sales (EPS about 36%/yr vs revenue 37%/yr). One year dips: EPS falls 68% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG72 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return-7%4

YTD return+78%10

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+48%9

3-year return+581%10

5-year return+68%6

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +581% over three years and +68% over five, ahead of 70% of the market.

It's up 48% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+78%).

WATCH

Returns sit at the market level over the past month (-5%) and over three months (-7%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on TG Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

TGTXTG Therapeutics

Revenue FY25$616M

GROWTH RATING↗

VERY STRONG97 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+505%10

Revenue, next 1Y+55%10

Revenue, next 3Y, CAGR+37%10

Revenue, next 5Y, CAGR+29%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-68%1

EPS growth, FY27E+174%10

EPS growth, FY28E+36%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 97% of companies worldwide.

Revenue grew 505%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 37%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 29%/yr over five years.10/10

WATCH

Revenue grew 505%/yr over the last 3 years; forecasts see it cooling to 37%/yr.

Earnings are set to grow in step with sales (EPS about 36%/yr vs revenue 37%/yr). One year dips: EPS falls 68% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG72 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return-7%4

YTD return+78%10

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+48%9

3-year return+581%10

5-year return+68%6

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +581% over three years and +68% over five, ahead of 70% of the market.

It's up 48% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+78%).

WATCH

Returns sit at the market level over the past month (-5%) and over three months (-7%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on TG Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community